You are here

Baxter & NY-Presbyterian/Weill Cornell Announce GAMMAGARD Study Data

Baxter International Inc. (NYSE: BAX) and New YorkPresbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer’s disease. Read More

News Category: